

Red fluorescent protein FusionRed

- Superior performance in fusions
- Low cytotoxicity
- Fast maturation, high pH-stability and photostability
- Proven suitability to generate stably transfected cell lines
- Recommended for protein labeling and long-term experiments

FusionRed is a red fluorescent protein characterized by improved performance in fusions and low toxicity [Shemiakina et al. 2012]. FusionRed lacks the residual tendency of other monomeric RFPs to dimerize at high concentration and behaves as a pure monomer at concentrations up to 10 mg/ml in HPLC analysis (Fig.2). Such "supermonomeric" properties ensure superior efficiency of FusionRed in protein labeling applications, especially in the cells with high expression level. Similarly to parental mKate2, FusionRed demonstrates fast maturation rate, high pH-stability and photostability, and significantly lower cytotoxicity than widely used mCherry [Shaner et al. 2004] and mRuby [Kredel et al. 2009]. FusionRed is mainly intended for protein labeling and long-term experiments including generation of transgenic animals.

Main properties of FusionRed

Characteristic	
Molecular weight, kDa	26
Polypeptide length, aa	232
Fluorescence color	red
Excitation maximum, nm	580
Emission maximum, nm	608
Quantum yield	0.19
Extinction coefficient, $M^{-1}cm^{-1}$	94 500
Brightness*	18.0
Brightness, % of EGFP	53
pKa	4.6
Structure	supermonomer**
Aggregation	no
Maturation half-time, min	130
Photostability, widefield***	150
Photostability, confocal***	176
Cell toxicity	not observed

* Brightness is a product of extinction coefficient and quantum yield, divided by 1 000.

** Purified recombinant protein behaves as a pure monomer at concentrations of 10 mg/ml as verified by high-performance liquid chromatography (HPLC)

*** Time to bleach 50% of fluorescent signal brightness.




Figure 1. FusionRed normalized excitation (thin line) and emission (thick line) spectra.

Complete FusionRed spectra in Excel format can be downloaded from the Evrogen Web site at <http://www.evrogen.com>




Figure 2. HPLC analysis of FusionRed in comparison with selected fluorescent proteins loaded in a high concentration.

FusionRed - red line, mKate2 - black line, mNeptune - gray line. Proteins were loaded at a concentration of 10 mg/ml. While HPLC demonstrates reversible dimerization of mKate2 and reveals a dimeric character for the mKate derivative, far-red fluorescent protein mNeptune [Lin et al. 2009], FusionRed behaves as a pure monomer. Data from Shemiakina et al. 2012.

Performance and use

FusionRed can be easily expressed and detected in a wide range of organisms. Mammalian cells transiently transfected with FusionRed expression vectors produce bright fluorescence in 10-12 hours after transfection. FusionRed performance in fusions has been demonstrated in a number of models.




Figure 3. FusionRed use for protein labeling in mammalian cells. Scale bar represents 10 μm . Images from Shemiakina et al. 2012.

Labeling efficiency testing


The performance of FusionRed and mCherry was directly compared in HeLa CCL2 cells for the following targets: connexin-43, endosomes, vinculin, and the Golgi complex. In this experiment, the cells were transfected with each of the four target fusions, fixed, and then compared for localization efficiency, which was determined by calculating the percentage of properly expressing cells versus the total number of transfected cells. FusionRed demonstrated clear advantage in all four fusions.

Cytotoxicity testing in HeLa cells

The cytotoxicity of FusionRed relative to selected red fluorescent proteins and EGFP was evaluated in the following experiment: HeLa cells were transfected with appropriate vectors encoding EGFP or one of the following red fluorescent proteins: mRuby, FusionRed, mKate2 or mCherry. Next, the EGFP-expressing cells were mixed with those expressing one of the RFPs, resulting in 4 separate cell mixtures: EGFP and mRuby, EGFP and FusionRed, EGFP and mKate2, and EGFP and mCherry. 48 hours after transfection, the green-to-red cell ratios were calculated utilizing flow cytometry and each of the cell mixtures were then plated into 3 plates. After additional 92 hour incubation, the green-to-red cell ratios were recalculated. Because only living cells were counted for this experiment, the difference between the ratios before and after the incubation can be assumed to accurately reflect RFP toxicity versus EGFP. mRuby exhibited a more than 10-fold higher cytotoxicity level compared to EGFP, while the remaining RFPs were almost as cytotoxic as EGFP in this experiment (Fig. 5).

Cytotoxicity testing in *Xenopus laevis* tadpoles

The eye formation is a complex multistage process that depends on many mechanisms, any disturbance of which may result in an abnormal phenotype. Here eye development was used as a sensitive readout of possible abnormal course of embryogenesis caused by expression of EGFP, FusionRed, and mCherry fusions (Fig. 6). In these experiments, actin and vimentin fusions of EGFP and FusionRed were only slightly more toxic than the uninjected controls, while expression of mCherry fusions led to notable decrease of the average eye size. Moreover, in many cases (80% of tadpoles with the reduced eye size), the reduced eye phenotype was accompanied by varying degree of an unclosed optic fissure, indicating an abnormal eye development (Fig. 7).



Stage 41 *Xenopus laevis* tadpoles expressing fluorescent protein fusions. Top panels: white light; bottom panels: fluorescence. Data from Shemiakina et al. 2012.




Figure 4. FusionRed and mCherry labeling efficiency testing. Data from Shemiakina et al. 2012




Figure 5. Protein cytotoxicity testing in HeLa cells. Data from Shemiakina et al. 2012





Figure 7. Top graph: Mean values of eye size of *Xenopus laevis* embryos injected with plasmids expressing different fluorescent protein fusions.

Bottom graph: Percentage of reduced eyes with unclosed optic fissure. Data from Shemiakina et al. 2012

Long-term expression

The excellent suitability of FusionRed for long-term experiments was proved both in experiments with stably transfected cell lines and in transgenic animals. In addition to its low cytotoxicity, FusionRed does not show abnormal lysosomal localization typical for many fluorescent proteins in long-term expression.




Figure 8. Being expressed in HeLa cells, both mKate2 and FusionRed remain evenly localized in cytoplasm after 96 hours of cultivation, while mCherry and mRuby show abnormal lysosomal localization. Data from Shemiakina et al. 2012.

Recommended filter sets and antibodies

FusionRed can be recognized using Anti-tRFP antibody (Cat.# AB233-AB234) available from Evrogen.

FusionRed can be detected using TRITC filter set or similar. Recommended Omega Optical filter sets are QMAX-Red and XF102-2.

Available variants and fusions

FusionRed mammalian expression vectors contain FusionRed coding sequence with codon usage optimized for high expression in mammalian cells, i.e. humanized [Haas et al. 1996]. Humanized FusionRed can also be expressed in *E. coli* and some other heterologous systems upon subcloning into appropriate vector.

The available vectors encoding FusionRed variants and fusions are listed below in the section FusionRed-related products. For most updated product information, please visit Evrogen website www.evrogen.com.

If you need FusionRed codon variant or fusion construct that is not listed on our website, please contact us at product@evrogen.com.

Licensing opportunities

Evrogen technology embodied in FusionRed is available for expanded and commercial use with an adaptable licensing program. Benefits from flexible and market driven license options are offered for upgrade and novel development of products and applications. For licensing information, please contact Evrogen at license@evrogen.com.

References

- Haas, J. et al. (1996). *Curr Biol*, 6 (3): 315–324 / pmid: 8805248
- Kredel, S. et al. (2009). *PLoS One*, 4 (2): e4391 / pmid: 19194514
- Lin, MZ et al. (2009). *Chem Biol*, 16 (11): 1169–79 / pmid: 19942140
- Shaner, NC et al. (2004). *Nat Biotechnol*, 22 (12): 1567–1572 / pmid: 15558047
- Shemiakina, II. et al. (2012). *Nat Commun*, 3: 1204 / pmid: 23149748

FusionRed-related products

Product	Cat.#	Description	Size
FusionRed expression/source vectors			
pFusionRed-C	FP411	Mammalian expression vector encoding humanized FusionRed and allowing its expression and generation of fusions to the FusionRed C-terminus	20 µg
pFusionRed-N	FP412	Mammalian expression vector encoding humanized FusionRed and allowing its expression and generation of fusions to the FusionRed N-terminus	20 µg
pFusionRed-actin	FP413	Mammalian expression vector encoding humanized FusionRed fused with human cytoplasmic β -actin	20 µg
pFusionRed-annexin	FP414	Mammalian expression vector encoding humanized FusionRed fused with human annexin	20 µg
pFusionRed-CD151	FP415	Mammalian expression vector encoding humanized FusionRed fused with human CD151	20 µg
pFusionRed-Cx26	FP416	Mammalian expression vector encoding humanized FusionRed fused with rat connexin 26	20 µg
pFusionRed-Cx43	FP417	Mammalian expression vector encoding humanized FusionRed fused with rat connexin 43	20 µg

Product	Cat.#	Description	Size
pFusionRed-f-mem	FP418	Mammalian expression vector encoding membrane-targeted FusionRed	20 µg
pFusionRed-Golgi	FP419	Mammalian expression vector encoding humanized FusionRed fused with human Golgi targeting sequence (GTS)	20 µg
pFusionRed-ER	FP420	Mammalian expression vector encoding humanized FusionRed targeted to the endoplasmic reticulum	20 µg
pFusionRed-H2B	FP421	Mammalian expression vector encoding humanized FusionRed fused with human histone H2B	20 µg
pFusionRed-laminB1	FP422	Mammalian expression vector encoding humanized FusionRed fused with human lamin B1	20 µg
pFusionRed-vimentin	FP423	Mammalian expression vector encoding humanized FusionRed fused with human cytokeratin-18	20 µg
pFusionRed-vinculin	FP424	Mammalian expression vector encoding humanized FusionRed fused with human vinculin	20 µg
pFusionRed-zyxin	FP425	Mammalian expression vector encoding humanized FusionRed fused with human zyxin	20 µg
pFusionRed-actinin	FP426	Mammalian expression vector encoding humanized FusionRed fused with human α -actinin	20 µg
pFusionRed-endo	FP427	Mammalian expression vector encoding humanized FusionRed fused with human RhoB protein	20 µg
pFusionRed-MAP4	FP428	Mammalian expression vector encoding humanized FusionRed fused with microtubule binding domain of mouse microtubule-associated protein 4 (MAP4)	20 µg
pFusionRed-paxillin	FP429	Mammalian expression vector encoding humanized FusionRed fused with chicken paxillin	20 µg
pFusionRed-PDHA1	FP430	Mammalian expression vector encoding humanized FusionRed fused with human pyrovate dehydrogenase (lipoamide) α 1 (PDHA1)	20 µg
pFusionRed-Rab5a	FP431	Mammalian expression vector encoding humanized FusionRed fused with human Ras-related protein Rab-5A	20 µg
pFusionRed-talin	FP432	Mammalian expression vector encoding humanized FusionRed fused with mouse talin-1 protein	20 µg
pFusionRed-tubulin	FP433	Mammalian expression vector encoding humanized FusionRed fused with human α -tubulin	20 µg
pFusionRed-cadherin	FP434	Mammalian expression vector encoding humanized FusionRed fused with human VE-cadherin	20 µg
pFusionRed-CDC42	FP435	Mammalian expression vector encoding humanized FusionRed fused with human CDC42	20 µg
pFusionRed-myosin	FP436	Mammalian expression vector encoding humanized FusionRed fused with mouse myosin regulatory light polypeptide 9	20 µg
pFusionRed-PCNA	FP437	Mammalian expression vector encoding humanized FusionRed fused with human PCNA	20 µg
pFusionRed-B	FP438	Bacterial expression vector; source of the FusionRed coding sequence	20 µg
Antibodies against FusionRed			
Anti-tRFP	AB233	Rabbit polyclonal antibody against TurboRFP, TurboFP602, TurboFP635, TurboFP650,	100 µg
	AB234	NirFP, TagBFP, TagRFP, FusionRed, TagFP635, mKate2 and PA-TagRFP	200 µg

Please contact your local distributor for exact prices and delivery information.

Notice to Purchaser:

FusionRed-related materials (also referred to as "Products") are intended for research use only. The Products are covered by European Pat. 1994149 and other Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License #001: <http://www.evrogen.com/products/Evrogen-FP-license.shtml>.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839, and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

MSDS information is available at <http://www.evrogen.com/MSDS.shtml>